Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)

Prophylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust protective efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years, with a focus on girls aged 9-14 years.Additionally, vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender-neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high-risk and special populations, including individuals with HPV infection or cytological abnormalities, those with a history of HPV-related lesions, genetically susceptible populations, individuals with high-risk lifestyle behaviors associated with cervical cancer, and immunocompromised patients.Regular cervical cancer screening remains essential post-vaccination.